--- title: A Gene-Editing Cure for Sickle Cell Now Works in the Patients Who Need It Most description: A young Nigerian woman went 18 months without a pain crisis after a new gene-editing therapy. The harder problem is who can actually get a cure. author: Darie Nani (Editor-in-Chief) updated: 2026-09-08T05:17:45.189Z canonical: https://richhealthmagazine.com/article/gene-editing-sickle-cell-cure-endemic-patients image: https://cdn.nanimediahouse.com/gene-editing-sickle-cell-268707.webp categories: Longevity & Science content_type: Analysis region: Global publication: Rich Health Magazine schema_type: Article --- A 21-year-old woman in Nigeria used to count her sickle cell pain crises by the year. In the twelve months before her treatment she had more than four of the vaso-occlusive episodes that define the disease, the ones that send sickled blood cells jamming into vessels and leave a person doubled over in pain, often in a hospital bed. Since her treatment she has had none. At the last check in the study that reported her case, she had gone 18 months without a single crisis. Her treatment was a gene-editing therapy, and her result is the reason a study published this week matters. Doctors already know they can cure sickle cell disease. What almost nobody has been able to answer is whether that cure will ever reach the people who actually live with the disease, most of whom are in Africa and India. The young woman from Nigeria is a small, concrete piece of evidence that it might. ## The cure exists, and it costs $2.2 million The first gene-editing cure for sickle cell, Casgevy, was approved by the US Food and Drug Administration on December 8, 2023. It was the first therapy of any kind to use CRISPR, and it works by a trick of biology: it switches the body's fetal hemoglobin back on. Fetal hemoglobin is the form of the oxygen-carrying protein that babies make before birth. Adults normally stop producing it, but in people whose adult hemoglobin is broken, coaxing the fetal version back into service can compensate for the defect that causes both sickle cell disease and beta-thalassemia. The problem is the price and the process. Casgevy carries a list price of $2.2 million for its one-time course. Before a patient can receive it, they have to undergo chemotherapy to clear out their bone marrow, then spend months in the hospital while their immune system rebuilds. In practice, only a wealthy health system can deliver it. Africa and India are home to most of the world's people with sickle cell, and many of those patients die in childhood. In much of sub-Saharan Africa, even hydroxyurea, the old standard drug that costs roughly $67 per person a year, is not reliably available. ## The new patients came from Nigeria and South and Southeast Asia The Chinese biotech CorrectSequence Therapeutics and its collaborators published their results on September 7, 2026, in the journal Cell Stem Cell. Their therapy uses a technique called base editing, which changes individual letters of DNA without cutting through both strands the way the original CRISPR method does. Researchers pursue base editing precisely because it avoids that double-strand cut, which they believe makes it a cleaner way to rewrite a gene. In these patients, the team edited a control region in each person's own blood stem cells, taken out, edited, and returned, to switch fetal hemoglobin back on. It is the same biological goal as Casgevy, reached by a more precise tool. What sets this report apart is who was in it. An earlier study, published in Nature this year, had followed five thalassemia patients in China, all of whom stopped needing blood transfusions. The new study adds four patients from outside China: the woman with sickle cell disease from Nigeria, and three thalassemia patients from Laos, Malaysia and Pakistan, ranging in age from 3 to 29. Their genetic mutations differed from one another and from the Chinese patients, which the researchers say is the point. Sickle cell and thalassemia are among the most common inherited single-gene disorders, with more than 300,000 sickle cell births and more than 40,000 thalassemia births worldwide each year, and the exact mutations behind them vary widely from one population to another. A therapy that works across those different genetic backgrounds is a therapy that could travel. ## Her blood counts turned within three months For the young woman from Nigeria, the study reports a clear turn. Her total hemoglobin rose from 7.7 to 12.9 grams per deciliter by the third month and stayed above 11. Her fetal hemoglobin, the protein the therapy was meant to reawaken, climbed from 3.5% to 62.2%, while her sickle hemoglobin fell from 76.1% to 31.6%. Across the three thalassemia patients, mean hemoglobin reached about 11.6 grams per deciliter, and at a median of 17.5 months of follow-up all three had stopped needing the transfusions they once depended on. The researchers report no detectable off-target edits, meaning no unintended changes elsewhere in the DNA, and no treatment-related serious adverse events in these patients. The company also reports that its base-editing approach produced faster engraftment than the two CRISPR-cutting methods it compared against, with treated cells taking hold in the neutrophil count at 13 days. These are strong early signs. The follow-up runs 15.5 to 17.5 months, with the Nigerian patient now at 18 months free of crises as of August 2026. That is encouraging, but it is too short to call a lifelong cure. What the study shows is remission and freedom from transfusions at this point in time, in patients whose disease looks, at these genetic sites, like the disease carried by millions of others. Whether that holds for years, and whether an edited-cells therapy can ever be delivered without the chemotherapy and long hospital stays that put a cure out of reach, are the questions the next chapter has to answer. For now, one woman in Nigeria has had a year and a half without the pain that used to organize her life. ## FAQ **Q: How much does a gene-editing cure for sickle cell cost?** Casgevy's list price is $2.2 million for the one-time course. For context, living with the disease is expensive too: in the United States, where about 100,000 people have sickle cell, the lifetime medical cost averages around $1.7 million per person. **Q: Is base editing better than the original CRISPR?** Base editing changes single DNA letters instead of cutting through both strands, and researchers favor it because avoiding that double-strand break is expected to be cleaner. It is a claimed advantage still being tested, not a settled outcome. Base-editing therapies for these blood disorders have been in human trials since 2021. **Q: Can patients get this new therapy now?** No. The CorrectSequence results are an early-stage study, and the therapy is not approved by the FDA or any other regulator. The only gene-editing cure approved anywhere so far is Casgevy, cleared in the United States in late 2023.